GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

GLP-1 agents "have an intricate web of various effects," Al-Aly said in a press briefing. For example, the analysis showed ...

At the J.P. Morgan Health Care conference this week in San Francisco, drugmakers had their sights set on the next generation of GLP-1 medications, alternatives, and a growing list of indications ...

These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion by 2031. Our report on the obesity drug market ...

This is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk. CivicScience has data on over 135K GLP-1 users, providing a unique lens into ...

With one in eight Americans having taken a GLP-1 already — including 43% of those with diabetes and a quarter of people with heart disease — it’s time to shift our thinking on GLP-1s to ...

ITOT iShares Core S&P Total U.S. Stock Market ETF ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

One hormone found in platypus venom, glucagon-like peptide-1 (GLP-1), plays a role in increasing insulin and regulating blood sugar levels, which could potentially help with new diabetes treatments.